Abstract
Targeted alpha therapy is an advancing experimental therapy that holds promise to deliver high cytotoxicity to targeted cancer cells. Initially thought to be indicated for leukaemia and micrometastases, there is now evidence that solid tumours can also be regressed. Alpha therapy may be molecular or physiological in its targeting. Alpha emitting radioisotopes such as Bi-212, Bi-213, At-211 and Ac-225 are used to label monoclonal antibodies or proteins that target specific cancer cells. Alternatively, radium- 233 is used for palliative therapy of breast and prostate cancers as it is a bone seeking element. Progress in the development of clinical trials of alpha therapy is examined for leukaemia, lymphoma, melanoma, glioblastoma multiforme, bone metastases, ovarian cancer, pancreatic cancer and other cancers. Results of past and current trials are reviewed, and the bases of some proposed trials are presented.
Keywords: Targeted Alpha Therapy, cancer cells, leukaemia, micrometastases, radioisotopes, lymphoma, pancreatic cancer
Reviews on Recent Clinical Trials
Title: Clinical Trials of Targeted Alpha Therapy for Cancer
Volume: 3 Issue: 3
Author(s): Barry J. Allen
Affiliation:
Keywords: Targeted Alpha Therapy, cancer cells, leukaemia, micrometastases, radioisotopes, lymphoma, pancreatic cancer
Abstract: Targeted alpha therapy is an advancing experimental therapy that holds promise to deliver high cytotoxicity to targeted cancer cells. Initially thought to be indicated for leukaemia and micrometastases, there is now evidence that solid tumours can also be regressed. Alpha therapy may be molecular or physiological in its targeting. Alpha emitting radioisotopes such as Bi-212, Bi-213, At-211 and Ac-225 are used to label monoclonal antibodies or proteins that target specific cancer cells. Alternatively, radium- 233 is used for palliative therapy of breast and prostate cancers as it is a bone seeking element. Progress in the development of clinical trials of alpha therapy is examined for leukaemia, lymphoma, melanoma, glioblastoma multiforme, bone metastases, ovarian cancer, pancreatic cancer and other cancers. Results of past and current trials are reviewed, and the bases of some proposed trials are presented.
Export Options
About this article
Cite this article as:
Allen J. Barry, Clinical Trials of Targeted Alpha Therapy for Cancer, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700339
DOI https://dx.doi.org/10.2174/157488708785700339 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Insights into the Biological Evaluation of Pterocarpanquinones and Carbapterocarpans with Anti-tumor Activity against MDR Leukemias
Anti-Cancer Agents in Medicinal Chemistry An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Myokines in Myogenesis and Health
Recent Patents on Biotechnology Antimicrobial Activity of Phenolics and Glucosinolate Hydrolysis Products and their Synergy with Streptomycin against Pathogenic Bacteria
Medicinal Chemistry